Assignee
SIGNALRX PHARMACEUTICALS INC
US·9 granted patents·2 pending applications·37 citations·filing 2013–2023
Top patents by PatentIndex Score
11 records- 0193US9505780B2Thienopyranones as kinase and epigenetic inhibitorsSIGNALRX PHARMACEUTICALS INC·Filed 2015·Granted Nov 29, 2016·9 cites·2 claims
- 0291US10308662B2Thienopyranones as kinase and epigenetic inhibitorsSIGNALRX PHARMACEUTICALS INC·Filed 2017·Granted Jun 4, 2019·6 cites·11 claims
- 0389US9981983B2Thienopyranones as kinase inhibitorsSIGNALRX PHARMACEUTICALS INC·Filed 2016·Granted May 29, 2018·5 cites·4 claims
- 0489US9550790B2Thienopyranones as kinase inhibitorsSIGNALRX PHARMACEUTICALS INC·Filed 2013·Granted Jan 24, 2017·8 cites·1 claims
- 0588US10174032B2Heterocyclic compound classes for signaling modulationSIGNALRX PHARMACEUTICALS INC·Filed 2015·Granted Jan 8, 2019·6 cites·2 claims
- 0679US11472814B2Thienopyranones and furanopyranones as checkpoint inhibitors and modulators of anti-tumor immunitySIGNALRX PHARMACEUTICALS INC·Filed 2018·Granted Oct 18, 2022·3 cites·18 claims
- 0774US12577254B2Thienopyranones and furanopyranones as kinase, bromodomain, and checkpoint inhibitorsSIGNALRX PHARMACEUTICALS INC·Filed 2023·Granted Mar 17, 2026·0 cites·6 claims
- 0858US2017101418A1Thienopyranones as Kinase and Epigenetic InhibitorsSIGNALRX PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 0957US11760762B2Thienopyranones and furanopyranones as kinase, bromodomain, and checkpoint inhibitorsSIGNALRX PHARMACEUTICALS INC·Filed 2018·Granted Sep 19, 2023·0 cites·6 claims
- 1054US2023165873A1Methods of Use for Single Molecule Compounds Providing Multi-Target Inhibition to Treat Covid 19SIGNALRX PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1144US12570668B2Single molecule compounds providing multi-target inhibition of BTK and other proteins and methods of use thereofSIGNALRX PHARMACEUTICALS INC·Filed 2019·Granted Mar 10, 2026·0 cites·19 claims
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →